Literature DB >> 20353669

Non-cancer medications for patients with incurable cancer: time to stop and think?

Peter S Hall, Simon R Lord, Ahmed El-Laboudi, Matthew T Seymour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20353669      PMCID： PMC2845486          DOI： 10.3399/bjgp10X483887

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  7 in total

Review 1.  Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease.

Authors:  P R Hebert; M Moser; J Mayer; R J Glynn; C H Hennekens
Journal:  Arch Intern Med       Date:  1993-03-08

2.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

3.  Mortality from major cancer sites in the European Union, 1955-1998.

Authors:  F Levi; F Lucchini; E Negri; P Boyle; C La Vecchia
Journal:  Ann Oncol       Date:  2003-03       Impact factor: 32.976

4.  Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.

Authors:  P J Devereaux; Homer Yang; Salim Yusuf; Gordon Guyatt; Kate Leslie; Juan Carlos Villar; Denis Xavier; Susan Chrolavicius; Launi Greenspan; Janice Pogue; Prem Pais; Lisheng Liu; Shouchun Xu; German Málaga; Alvaro Avezum; Matthew Chan; Victor M Montori; Mike Jacka; Peter Choi
Journal:  Lancet       Date:  2008-05-12       Impact factor: 79.321

5.  Management and survival trends in advanced colorectal cancer.

Authors:  T Price; K Pittman; W Patterson; M Colbeck; N Rieger; P Hewett; D Rodda; A Townsend; G Maddern; C Luke; D Roder
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-06-03       Impact factor: 4.126

Review 6.  A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

Authors:  Nicole M Kuderer; Alok A Khorana; Gary H Lyman; Charles W Francis
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

7.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
  7 in total
  3 in total

1.  Inappropriate prescribing in patients accessing specialist palliative day care services.

Authors:  A Todd; H Nazar; H Pearson; L Andrew; L Baker; A Husband
Journal:  Int J Clin Pharm       Date:  2014-06

2.  Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage.

Authors:  Efty P Stavrou; Nicholas Buckley; Jake Olivier; Sallie-Anne Pearson
Journal:  BMJ Open       Date:  2012-05-21       Impact factor: 2.692

3.  Patterns of statin initiation and continuation in patients with breast or colorectal cancer, towards end-of-life.

Authors:  Amelia Smith; Laura Murphy; Kathleen Bennett; Thomas I Barron
Journal:  Support Care Cancer       Date:  2017-01-18       Impact factor: 3.603
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.